Advances in AI promise to transform drug discovery and development. AI not only brings more efficiency to today’s costly and slow processes but also holds the potential to identify entirely new drugs beyond the capabilities of today’s methods. As such, AI will increasingly become a key driver for competitiveness in life sciences, and biopharma executives need to ensure their companies build up the right capabilities — for example through deals and M&A.
In our latest paper, we explore ten years of deal-making in the sector to assess the impact that AI is having in drug discovery deals, how it will shape future M&A activity and why pharma companies need to adapt their approach to fully capitalise on the opportunity that AI presents.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
